The Pharmaceutical Grade Silica Gel Market is to Touch $101.1 Billion by 2030; Increasing Use of Silica Gel in Controlled-Release Medications and Strong Pharmaceutical Manufacturing Regulations Driving Quality Requirements propel market growth.

The Pharmaceutical Grade Silica Gel Market size is estimated to reach $101.1 billion by 2030, growing at a CAGR of 9.2% during the forecast period 2024-2030, according to a recent report published by IndustryARC, titled, “Pharmaceutical Grade Silica Gel Market – By Type (Liquid Silica Gel, Solid Silica Gel and Others), By Packaging Type (Packets, Pouch, Bag, Sachets and Others), By Application (Desiccant, Drug Carrier, Adsorbent, Glidants, Gas Drying, Filtration and Others), By Geography - Global Opportunity Analysis & Industry Forecast, 2024-2030”

Surge in demand for personalized medicine and specific formulations and Advancements in packaging technology improving drug storage are fueling the growth of the Pharmaceutical Grade Silica Gel industry during the forecast period.

Asia Pacific accounted for the largest share of 38% of the Pharmaceutical Grade Silica Gel Market in 2023. The region's robust pharmaceutical industry, which demands high-quality excipients for drug formulations and packaging drive the Pharmaceutical Grade Silica Gel market in Asia Pacific. The World Bank’s report with China predicts healthcare spending will reach USD 2.5 trillion by 2035 without reforms. This increase drives the demand for pharmaceutical-grade silica gel, crucial for moisture control and preservation in drug production. Regulatory changes and advanced manufacturing processes have improved product quality. Investments in R&D for drug delivery systems are fueling market growth, ensuring compliance with high-quality standards. Emerging markets are key contributors to the growing demand for these materials. This trend is expected to continue as healthcare infrastructure expands globally.

The rising prevalence of chronic diseases is driving demand for pharmaceutical-grade silica gel, vital in drug formulation and stabilization. According to the NIH/NLM, the number of individuals aged 50 and older with at least one chronic disease is projected to rise by 99.5%, from 71.522 million in 2020 to 142.66 million by 2050. This growing healthcare need is increasing the reliance on silica gel for its moisture-absorbing properties, which enhance the shelf life and efficacy of medicines. Consequently, the pharmaceutical industry’s demand for advanced excipients like silica gel is expected to continue growing, further boosting market expansion.

The surge in pharmaceutical production in North America and Europe drives the demand for pharmaceutical-grade silica gel. According to IQVIA in 2022, North America accounted for 52.3% of global pharmaceutical sales, while Europe contributed 22.4%. From 2017 to 2022, 64.4% of new medicines were sold in the U.S., compared to 16.4% in Europe. As production capacity expands, the need for excipients like silica gel grows. This material is crucial for stabilizing and improving drug formulations. Regulatory advancements and technological innovations further support this market's growth. Additionally, the increasing demand for advanced drug delivery systems fuels the use of silica gel in the pharmaceutical sector. 

• In May 2024, Sorbead India and Swambe Chemicals have merged to create Sorbchem India Private Limited, combining expertise to enhance desiccant and adsorbent solutions. Backed by Zeochem, the company aims to drive innovation, operational efficiency, and expand its product offerings while maintaining high-quality standards in the industry.

Key companies profiled in the Pharmaceutical Grade Silica Gel Market are Clariant International Ltd., Solvay S.A, The Dow Chemical Company, E. I. du Pont de Nemours and Company, Multisorb Technologies Inc., W. R. Grace & Co.-Conn, Evonik Industries, Desiccare Inc., Fuji Silysia Chemical, Sorbead India and Others.